Novartis Consumer Health, Inc. is voluntarily recalling certain lots of Triaminic® Syrups and Theraflu Warming Relief® Syrups that were manufactured in the United States prior to December 31, 2011.

Respiratory syncytial virus (RSV) is a very common virus that leads to mild, cold-like symptoms in adults and older healthy children. But it can be far more serious in infants and toddlers, especially those in certain high-risk groups.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the INCIVEK® (telaprevir) label in the United States has been updated to include a Boxed Warning stating that fatal and non-fatal serious skin reactions have been reported in patients taking INCIVEK combination treatment.

Gilead Sciences today announced topline results from the Phase 3 POSITRON study examining a 12-week course of once-daily sofosbuvir plus ribavirin ( RBV ) in patients with genotype 2 or 3 chronic hepatitis C virus ( HCV ) infection who are not candidates to take interferon ( IFN ).

GlaxoSmithKline announced today that the US Food and Drug Administration (FDA) has approved PROMACTA ® for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy.

Merck announced final results from the STARTMRK study – the longest double-blind Phase III non-inferiority study evaluating an integrase inhibitor in treatment-naïve adults with HIV-1.

Pfizer Inc. announced that it has stopped a Phase 3 clinical trial of Lyrica ( pregabalin ) in patients with neuropathic pain associated with HIV neuropathy, a form of nerve damage characterized by burning pain usually beginning in the feet.

Merck announced final results from a Phase III, open-label study designed to compare the impact of two anemia management strategies on sustained virologic response ( SVR ) in patients with chronic hepatitis C virus ( HCV ) genotype 1 infection treated with VICTRELIS  ( boceprevir ) in combination with PEGINTRON  ( peginterferon alfa-2b ) and ribavirin (P/R).

Janssen Therapeutics, Division of Janssen Products, LP, announced the U.S. Food and Drug Administration (FDA) has approved INTELENCE ® ( etravirine ) to be administered in combination with other antiretroviral ( ARV ) medications.

Pfizer Inc. announced  Prevnar 13 ( Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.